about
Utility of the RIG-I Agonist Triphosphate RNA for Melanoma TherapyRIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockadeSystemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model
P50
description
researcher
@en
wetenschapper
@nl
name
Lars M König
@en
Lars M König
@nl
type
label
Lars M König
@en
Lars M König
@nl
prefLabel
Lars M König
@en
Lars M König
@nl
P31
P496
0000-0002-8348-7787